q3 adjusted non-gaap earnings per share $2.39.
q3 revenue $7.2 billion versus refinitiv ibes estimate of $7 billion.
for q4 2021, company anticipates that non-gaap core revenue growth will be in low-to-mid teens percent range.
for full year 2021, company now anticipates that non-gaap core revenue growth rate including cytiva will be more than 20%.
